

# Transforming Growth Factor Market to Grow at 7.8% CAGR, Reaching US\$ 832.5 Million by 2034

*Discover the dynamic landscape of the transforming growth factor market driven by technological advancements, increasing healthcare expenditure.*

ROCKVILLE PIKE SUITE, ROCKVILLE, USA, May 28, 2024 /EINPresswire.com/

-- The global [transforming growth factor market](#) is estimated at US\$ 391.5 million in 2024, projected to grow steadily with a 7.8% CAGR through 2034. The market is projected to account for a valuation of US\$ 832.5

million by 2034. Transforming growth factor's (TGF) involvement in regulating cell growth, differentiation, and tissue repair presents significant therapeutic potential. Research into TGF-based therapies for conditions like cancer, fibrosis, autoimmune diseases, and tissue regeneration drives market growth.

The increasing incidence of chronic illnesses globally, where TGF pathways exert significant influence, highlights the necessity for therapies directed at these pathways. TGF's active participation in disease advancement intensifies the call for inventive treatments. TGF's role in governing cell growth, differentiation, and tissue repair holds immense promise for therapeutic applications. The ongoing exploration of TGF-based treatments for conditions such as cancer, fibrosis, autoimmune disorders, and tissue regeneration serves as a catalyst for the market's expansion.

Get Free Sample Copy of This

Report: [https://www.factmr.com/connectus/sample?flag=S&rep\\_id=9659](https://www.factmr.com/connectus/sample?flag=S&rep_id=9659)

Continuous advancements in biomedical research have uncovered the diverse roles of TGF in cellular processes, disease biology, and therapeutic applications. This ongoing exploration fuels the demand for TGF-related products and therapies. Growing regulatory support and approvals for TGF-related therapies and products bolster market confidence and facilitate their



commercialization, encouraging further investments and developments in this sector.

## Key Takeaways from the Market Study

The North American transforming growth factor market is projected to grow at a compound annual growth rate (CAGR) of 6.8% through 2034. In 2024, the United States is expected to dominate this market with a significant 91.5% share, valued at approximately US\$ 158 million. Meanwhile, the market in China is anticipated to expand at a robust CAGR of 13.3% over the same period. By product type, bone morphogenetic proteins (BMPs) are forecasted to account for a substantial 43.7% market share in 2024. Additionally, within applications, cell therapy and ex vivo manufacturing are expected to lead, commanding a 28.8% share in 2024.

“The increasing prevalence of chronic diseases and increasing drug development activities driving the transforming growth factor market.” remarks an analyst at Fact.MR.

## Competitive Landscape

Companies invest significantly in R&D to explore TGF's roles in various diseases and develop innovative therapies. They aim to identify novel targets within TGF pathways and create effective treatments. Market players expand their product portfolios to include a wide range of TGF-related products, such as antibodies, recombinant proteins, assays, and inhibitors, catering to diverse research and therapeutic needs.

Bio-Techne Corporation focuses on providing life science tools and solutions. They contribute to the TGF market through the development and distribution of recombinant proteins, antibodies, and assays used in TGF-related research and diagnostics.

Sartorius CellGenix GmbH provides cell culture media and reagents essential for cell therapy and biopharmaceutical production. Their offerings include solutions involving TGF to support cell culture processes and therapeutic development.

## More Valuable Insights

Fact.MR, in its new offering, presents an unbiased analysis of the global transforming growth factor market, presenting a historical analysis from 2019 to 2023 and forecast statistics for the period of 2024 to 2034.

The study reveals essential insights on the Type (GMP Grade, NON-GMP Grade) by Product type (Activin, Bone Morphogenetic Proteins (BMPs), TGF-beta protein) By Application (Oncology Research, Hematology Research, Wound Healing Research, Dermatology Research, Cardiovascular Disease & Diabetes, Cell therapy and Ex vivo manufacturing, Others) By End-User (Pharmaceutical and Biotechnology Companies, Research Centres & Academic Institutes, CMO and CDMO) across seven major regions (North America, Latin America, Western Europe, Eastern Europe, South Asia and Pacific, East Asia, Middle East and Africa).

Get Customization on this Report for Specific Research Solutions:

[https://www.factmr.com/connectus/sample?flag=RC&rep\\_id=9659](https://www.factmr.com/connectus/sample?flag=RC&rep_id=9659)

Explore More Related Studies Published by Fact.MR Research:

**Gelatin Bone Glue Market:** (□□□□□□□□□□) global gelatin bone glue market size was valued at US\$ 937.8 million in 2023 and is predicted to expand at a CAGR of 7.2% to reach US\$ 1.87 billion by the end of 2033.

**Facial Bone Contouring Market:** (□□□□□□□□)The global facial bone contouring market size is expected to surpass US\$ 452.6 million in 2024. Sales of facial bone contouring are anticipated to develop at a sluggish 1.8% CAGR between 2024 and 2034. It is projected that the demand for facial bone contouring is going to be valued at US\$ 541.3 million by 2034

About Fact.MR:

We are a trusted research partner of 80% of fortune 1000 companies across the globe. We are consistently growing in the field of market research with more than 1000 reports published every year. The dedicated team of 400-plus analysts and consultants is committed to achieving the utmost level of our client's satisfaction.

Contact:

US Sales Office

11140 Rockville Pike

Suite 400

Rockville, MD 20852

United States

Tel: +1 (628) 251-1583, +353-1-4434-232 (D)

Sales Team: [sales@factmr.com](mailto:sales@factmr.com)

Akshay Gorde

FactMR

[email us here](#)

Visit us on social media:

[X](#)

[LinkedIn](#)

[Other](#)

---

This press release can be viewed online at: <https://www.einpresswire.com/article/715212570>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire,

Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2024 Newsmatics Inc. All Right Reserved.